3Mckenzie R, Reynolds JC, O'Fallon A, et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol, 2000, 27: 2222-2226.
4Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid'induced osteaporosis: a meta-analysis. Osteoporos Int, 2002, 13: 777-787.
5Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone, 2006, 39: 253-259.
6American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum, 2001, 44: 1496-503.
7Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior cortieosteroid use and fracture risk. J Bone Miner Res, 2004, 19: 893-899.
8Kanish JA Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone, 2009, 44: 734-743.
9Van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM, 2005, 98: 191-198.
10Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a muhieentre, double-blind, double-dummy, randomised controlled trial. Lancet, 2009, 373: 1253-1263.
